USA: Pharmaceutical Business Pfizer Prices $ 5 Billion Debt Offering
Pfizer announced the pricing of a debt offering consisting of six tranches of notes with a total volume of $ 5 billion.
New York/USA — The company intends to use the net proceeds for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of its outstanding commercial paper. The closing of the offering is expected to occur on September 7, 2018, subject to satisfaction of customary closing conditions.
Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 45487300)